Israeli Biotech Kamada Surges as European Results Loom

Kamada Ltd.’s investors will find out by the end of this quarter whether they were right to bet on the maker of treatments for hereditary lung disease getting close to a major expansion in Europe.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.